BioXcel Therapeutics, Inc. Increase (Decrease) in Accounts and Other Receivables
BioXcel Therapeutics, Inc. (BTAI) reported Increase (Decrease) in Accounts and Other Receivables of -$151.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-08-13
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-06-30 was -$134.00K, a 888.24% decline year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was -$17.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was $233.00K, a 82.03% increase year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was -$17.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2025 was $102.00K, a 70.00% increase from fiscal 2024.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2024 was $60.00K.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2023 was -$177.00K, a 171.37% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2022 was $248.00K.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$151.00K 10-Q · filed 2026-08-13 | $82.00K derived: sum of 3 quarters · filed 2026-08-13 | $65.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$17.00K 10-Q · filed 2026-05-15 | $216.00K derived: sum of 2 quarters · filed 2026-05-15 | $199.00K derived: sum of 3 quarters · filed 2026-05-15 | $216.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $216.00K derived: sum of 2 quarters · filed 2026-03-27 | $233.00K derived: sum of 3 quarters · filed 2026-08-13 | $102.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | -$131.00K 10-Q · filed 2025-11-12 | -$3.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$114.00K 10-Q · filed 2026-08-13 | $14.00K derived: sum of 3 quarters · filed 2026-08-13 | -$795.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$131.00K 10-Q · filed 2026-05-15 | -$3.00K derived: sum of 2 quarters · filed 2026-05-15 | -$812.00K derived: sum of 3 quarters · filed 2026-05-15 | -$378.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$681.00K derived: sum of 2 quarters · filed 2026-03-27 | -$247.00K derived: sum of 3 quarters · filed 2026-03-27 | $60.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$809.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$375.00K derived: sum of 2 quarters · filed 2025-11-12 | -$68.00K 10-Q · filed 2025-11-12 | -$732.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $434.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $741.00K 10-Q · filed 2025-08-12 | $77.00K derived: sum of 3 quarters · filed 2025-08-12 | $381.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $307.00K 10-Q · filed 2025-05-12 | -$357.00K derived: sum of 2 quarters · filed 2025-05-12 | -$53.00K derived: sum of 3 quarters · filed 2025-05-12 | $95.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$360.00K derived: sum of 2 quarters · filed 2025-03-28 | -$212.00K derived: sum of 3 quarters · filed 2025-03-28 | -$177.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $452.00K derived: sum of 2 quarters · filed 2024-11-14 | $487.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $183.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $35.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $248.00K 10-K · filed 2024-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |